Online ISSN: 2515-8260

Keywords : calcipotriol


A comparative study of efficacy and safety of topical calcipotriol and topical dithranol in chronic plaque psoriasis

Yadav Nihal, Prabhakar M Sangolli, Adarsh Gowda

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 2, Pages 325-331

Background: Psoriasis is chronic inflammatory dermatosis with genetic background. Topical therapy
alone is effective in localized psoriasis
Objective: Study was conducted to compare the efficacy and safety of topical calcipotriol and dithranol
in mild chronic plaque psoriasis with less than 10% BSA involvement
Methods: Study duration was 6 weeks. Thirty patients each were included in two groups. In calcipotriol
group, patients applied calcipotriol ointment (0.005%) twice daily. In dithranol group patients applied
1% ointment in 1st week, 2% ointment during 2nd week, 3% ointment from 3rd weeks onwards. Duration
of application was 60 minutes, once daily.
Results: Patients responded to both the treatments satisfactorily. However, calcipotriol was superior in
efficacy. Patients in both the groups tolerated the treatment.
Conclusion: Both calcipotriol and dithranol (short contact therapy) were effective in the treatment of
mild chronic plaque psoriasis. Even though, dithranol is less potent, it is cost effective.

A hospital based assessment of the effects of various topical agents in chronic plaque type psoriasis

Dr. Shribhagawan Rolaniya, Dr. Apeksha Singh

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 2, Pages 1005-1008

Aim: To determine the effect of various topical agents in chronic plaque type psoriasis.
Materials and Methods: The study was carried out on patients having chronic plaque type psoriasis vulgaris came to Department of Skin & VD, Medini Rai Medical College, Palamu, Jharkhand, India. Total 300 patients were enrolled and were divided into three groups comprising of 100 patients in each group. Group A patients were asked to apply ammonium lactate twice a day, Group B patients were asked to apply ammonium lactate in morning and clobetasol propionate in evening, Group C patients were asked to apply topical ammonium lactate in morning and calcipotriol in evening.
Results: Physician global assessment scale shows that in Group A, 39% patients had excellent response, 15% patients had good response, and 21% patients had fair response whereas 25% patients had poor response. In group B, 35% patients had excellent response, 29% patients had good response, and 17% patients had fair response whereas 19% patients had poor response. In group C, 31% patients had excellent response, 28% patients had good response, and 22% patients had fair response whereas 19% patients had poor response.
Conclusion: Combination therapy is effective, well tolerated with minimal side effects and better compliance was seen with patients. Ammonium lactate 12% can also be considered as one of the topical option as a monotherapy and also as a maintenance therapy.